- AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012
- AcelRx Pharmaceuticals Reports Third Quarter 2011 Financial Results
- AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
- AcelRx Pharmaceuticals Reports Second Quarter 2011 Financial Results
- AcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013
About AcelRx
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. We were founded to solve the problems of post-operative intravenous patient-controlled analgesia (IV PCA). Our lead product, ARX-01, is designed to address IV PCA problems which can cause harm to patients following surgery such as the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.
